| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-07-21 | anetumab ravtansine (BAY 94-9343) | mesothelioma | 2 | Bayer Healthcare (Germany) MorphoSys (Germany) Immunogen (USA - MA) | Cancer - Oncology |
| 2017-07-21 | JX-594/TG6006 (Pexa-Vec -pexastimogene devacirepvec) | hepatocellular carcinoma (HCC) | 3 | Transgene (France) Sillajen (Republic of Korea) | Cancer - Oncology |
| 2017-07-19 | IFN alpha Kinoid | dermatomyositis | 2a | Neovacs (France) | Autoimmune diseases - Dermatological diseases - Rare diseases |
| 2017-07-19 | Macuneos (formerly BIO201) | age related macular degeneration (AMD) | 1-2 | Biophytis (France) | Ageing diseases - Ophtalmological diseases |
| 2017-07-18 | EB-101 (gene corrected skin grafts) | dystrophic epidermolysis bullosa, | 3 | Abeona Therapeutics (USA - NY) | Rare diseases - Genetic diseases - Dermatological diseases |
| 2017-07-17 | STRO-001 | non-Hodgkin lymphoma, multiple myeloma | preclinical | Sutro Biopharma (USA - CA) | Cancer - Oncology |
| 2017-07-17 | WVE-120101 | Huntington’s disease | 1-2 | Wave LIfe Sciences (USA - MA) | Rare diseases - Genetic diseases - Neurodegenerative diseases |
| 2017-07-17 | WVE-120102 | Huntington's disease | 1-2 | Wave LIfe Sciences (USA - MA) | Rare diseases - Genetic diseases - Neurodegenerative diseases |
| 2017-07-17 | flotetuzumab - MGD006 | relapsed or refractory acute myeloid leukemia | 1 | Macrogenics (USA - Md) Servier (France) | Cancer - Oncology |
| 2017-07-15 | RNAntibody® technology | preclinical | Curevac (Germany) | Cancer - Oncology - Infectious diseases | |
| 2017-07-13 | voretigene neparvovec - SPK-RPE65 | inherited retinal dystrophy (IRD) caused by RPE65 mutations - Leber Congenital Amaurosis (LCA) 2 | 3 | Spark Therapeutics (USA - PA) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-07-12 | ABX464 | inflammatory bowel disease | preclinical | Abivax (France) | Inflammatory diseases - Gastrointestinal diseases |
| 2017-07-11 | Praxbind® (idarucizumab) | specific antidote for Pradaxa® (dabigatran etexilate) - reversion of the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure. | 3 | Boehringer Ingelheim (Germany) | Cardiovascular diseases - Cerebrovascular diseases |
| 2017-07-11 | Austedo™ (SD-809 - deutetrabenazine) | chorea associated with Huntington disease | 3 | Teva Pharmaceutical Industries (Israel) | Neurodegenerative diseases - Rare diseases |
| 2017-07-11 | AAV5-hFIX - AMT-060 | hemophilia B | 1-2 | uniQure (The Netherlands) Chiesi Farmaceutici (Italy) | Genetic diseases- Hematological diseases - Rare diseases |
| 2017-07-10 | ExOlin® | type 1 diabetes, type 2 diabetes | Defymed (France) | Metabolic diseases | |
| 2017-07-10 | MDG1011 | advanced hematological diseases, namely acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM) | 1-2 | Medigene (Germany) | Cancer - Oncology |
| 2017-07-10 | NKTR-358 | preclinical | Nektar Therapeutics (USA - CA) | Autoimmune diseases – Inflammatory diseases | |
| 2017-07-10 | Cabometyx™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) | previously untreated, advanced or metastatic renal cell carcinoma | 3 | Exelixis (USA - CA) BMS (USA - NY) | Cancer - Oncology |
| 2017-07-08 | Translarna™ (ataluren) | nonsense mutation Duchenne Muscular Dystrophy (nmDMD) | 3 | PTC Therapeutics (USA - NJ) | Rare diseases - Neuromuscular diseases |
